Peptide with regulating biological activity on protein synthesis in hepatocytes


The invention relates to medical Bioorganic chemistry, namely the synthesis of peptides. Declared a new heptapeptide lysyl-glutamyl-aspartyl-alanyl-prolyl-glycyl-Proline General formula Lys-Glu-Asp-Ala-Pro-Gly-Pro with stimulating and regulating effect on protein synthesis in hepatocytes. The proposed heptapeptide has the ability to affect biochemical parameters of the endogenous opioid system. Heptapeptide has no psychotropic effects and does not affect psychomotor activity of animals used in behavioral tests. The proposed heptapeptide can be used as the basis for the development of dosage forms that have hepatoprotective activity. 1 Il., table 4.

The invention relates to medical biochemistry, in particular to a new heptapeptide possessing prolonged regulating and stimulating effect on protein synthesis in rat hepatocytes and free from side of psychotropic activity. Especially significant prolonged regulatory and catalytic activity has been detected in the hepatocytes of aged rats, which makes it promising to create on the basis of heptapeptide drugs with gerontological the hepatocytes of the liver, but lose synchronization protein synthesis [1].

Known Tripeptide of the formula Gly-His-Lys, which in regulatory concentrations can increase the intensity of protein synthesis in hepatocytes [2] . However, data on the influence of Tripeptide on the intensity of protein synthesis in monolayer cultures with a dense arrangement of hepatocytes were obtained in poor environments. The use of the environment, ensuring the full functioning of hepatocytes, completely removes the positive impact of Tripeptide.

Known tetrapeptide formula Lys-Glu-Asp-Ala with the ability to stimulate the functional activity of hepatocytes (patent of the Russian Federation 2166957 And 61 To 38/07, 2001) [3]. This tetrapeptide valid regulatory concentrations and increases the intensity of protein synthesis in monolayer cultures with a dense arrangement of hepatocytes in environments that ensure full functioning hepatocytes. However, this tetrapeptide has no prolonged regulating biological activity on protein synthesis in hepatocytes and has adverse psychotropic effects.

The invention was the creation of a biologically active peptide drug that has prolongirovannami and free from adverse psychotropic action.

The problem is solved by the synthesis of new heptapeptide lysyl-glutamyl-aspartyl-alanyl-prolyl-glycyl-Proline General formula Lys-Glu-Asp-Ala-Pro-Gly-Pro, built only from natural amino acids. Heptapeptide Lys-Glu-Asp-Ala-Pro-Gly-Pro, responsive to the invention, exhibits biological activity, and it has prolonged stimulatory effect on the amplitude and rhythm of protein synthesis in hepatocytes and is free from side of psychotropic activity.

Synthesis of the proposed heptapeptide performed on the peptide synthesizer, Applied Biosystems A disclosability method in the presence of 1-hydroxybenzotriazole using 9 fluorenylmethyl-carbonyl-(Fm)-protected amino acids.

As solid phase synthesis of heptapeptide use resin p-Benzyloxybenzyl Alcohol Resin (Novabiochem). Removing the peptide from the resin and the hydrolysis of the protective groups is carried out by treatment for 2 hours in nitrogen atmosphere a mixture consisting of triperoxonane acid (90%), water (5%) and ethicial (5%). The mixture was concentrated in vacuo, the peptide precipitated by cold dry ether. The resulting heptapeptide was purified by chromatography on a HPLC column (Kromasil 18 h mm, 7 μm, using a gradient elution of water-acetonitrile containing 0.1% triperoxide A. Use the gradient 20-60% B over 40 minutes Collect the fraction 28-34 minutes the Collected fraction is evaporated under reduced pressure on a rotary evaporator to dryness. Get 11 mg of white product, which was dissolved in buffer a and injected into the same column for rechromatography. The detection is carried out at a wavelength of 220 nm. Collect peak with a retention time of 32 minutes. The product is evaporated under reduced pressure, and then twice with ethanol. The product is dissolved in water and subjected to freeze drying. Receive 10 mg of a white lyophilized product. So pl. 132-136oC.

The product analysis is carried out using thin-layer chromatography on plates with silica gel firm Silufol. Chromatographic mobility (Rf) for heptapeptide in the solvent system chloroform : methanol : ammonia (6:4:1) is 0.42. Check the homogeneity of the peptide was performed using analytical HPLC on Kromasil column 18 4x150 mm 5 μm, using a gradient elution of water-acetonitrile with a flow rate of eluent, 1 ml/min Eluent A - 0,1% triperoxonane acid, eluent B to 40% acetonitrile in buffer A. Using a gradient of 30-50% B in 20 minutes Detection is carried out at a wavelength of 220 nm. Heptapeptide chromatographies one peak. The basic substance content of 98.5%.

AAVA of heptapeptide testify, the composition corresponds to that specified for the synthesis of the structure.

Example 1. Activity proposed heptapeptide to influence the intensity of protein synthesis was assessed by its impact on the intensity of protein synthesis in monolayer cultures of hepatocytes. Compared the activity of the proposed heptapeptide and known tetrapeptide Lys-Glu-Asp-Ala.

For isolation of hepatocytes of the liver of rats was perfesional Beccalli the Hanks solution with 0.5 mm of EGTA and then 0.05% collagenase solution in medium 199. The cell suspension was filtered and centrifuged. A suspension of hepatocytes at a concentration of 5105introduced in Petri dishes, at the bottom of which were glass coated with collagen. Used medium 199 without bovine serum with addition of 0.2 mg/ml albumin and 5 μg/ml insulin. Previously it was found that in such an environment, the fusion protein is as intense as in medium 199 with bovine serum, and morphology of cells fully preserved [4]. Cup with glass was placed in a thermostat at 37oWith aerated by air with the addition of CO2. After 2 hours, the glass adherent cells were washed and the medium was replaced with the same. Through the day, washout of the culture studied protein synthesis in cultures. When pointed to by the tov.

The intensity of protein synthesis was measured by incorporation of [3H]leucine adjusted pool of free amino acids in the same culture. Expected relative incorporation of [3H]leucine (ISOP), correcting the intensity of synthesis as from the variability of the pool, and from differences in the number of cells in different cultures. When assessing the level of protein synthesis was calculated the average value for 5-7 cultures. Kinetics of synthesis was determined in samples from three cultures (each culture was measured individually), which were taken at intervals of 10 minutes for 2 hours. In this case, the average level of synthesis is believed to 36 cultures. Culture of hepatocytes incubated for 10 minutes in an environment with a volume concentration of 30 µci/ml of [3H]leucine with molar activity 150 CI/mm. Samples containing heptapeptide and tetrapeptide, compared with control, which was cultured in the same conditions, but without addition of peptide.

After incubation, the culture with labeled leucine laundered environment and to highlight neuklyuzhego leucine (pool) was treated with cold (4oC) perchloric acid 90 minutes of the same culture was washed with ethanol and then dissolved proteins gianina. Radioactivity pool of free intracellular and counter SL-30.

The intensity of protein synthesis was calculated by the formula: Icorr=IiX Pav/Pi(CPM), where Ii- the measured radioactivity of proteins of a certain culture, i, Pi- the total radioactivity of proteins and pool of the same culture, Pavthe average radioactivity of proteins and the pool of cultures of this experience, Icorr- incorporation of leucine-adjusted pool of free leucine.

The data obtained on the effect of heptapeptide with a concentration of 0.005 ág/ml (6 nmol/l) for 2, 4 and 24 hours. After 4-hour incubation of hepatocytes 4-month-old rats with heptapeptides with a concentration of 0.005 ág/ml found a significant increase in the intensity of protein synthesis (Icorr12%. 24 hours after injection of heptapeptide in cell culture of hepatocytes, the value of Icorrsignificantly increased by 25%. Tetrapeptide also has a positive effect on protein synthesis, however, as follows from the results in table 1, the positive effects decreases with increasing exposure time from 4 to 24 hours. The increase of Icorrfor tetrapeptide 24 hours is 9%, which is considerably less than that observed when the 4 hour its impact and is 27%. Thus, heptapeptide has Pro is considerably reduced and it does not have a prolonged effect.

Heptapeptide has a more significant effect on the hepatocytes old rats than in young rats. To control for 18-month-old rats Icorris 180, and under the influence of heptapeptide for 4 hours increased to 226, there is a significant increase of 26%. At 24-hour exposure heptapeptide at a concentration of 0.005 ág/ml (6 nmol) its influence increases. There is almost double the growth in the value of Icorrintensity of protein synthesis. Along with the increase of protein synthesis is a significant increase in the amplitude of the rhythm synthesis 1.46 times (drawing). The amplitude of the rhythm of protein synthesis in culture characterizes the degree of synchronization of cell metabolism. In hepatocytes old rats there was a significant decrease in the amplitude of the rhythm of protein synthesis, and under 24-hour exposure heptapeptide observed a significant increase in protein synthesis and amplitude of its rhythm. Thus, under the action of heptapeptide hepatocytes old rats functionally begin to resemble hepatocytes young rats. Due to its unique structure claimed heptapeptide has a prolonged positive activity in cell culture, while tetrapeptide prolongiruetsa white rats-males were evaluated in tests "Auto-Track System" (ATS) and elevated plus maze (PC). Compared the activity of the proposed heptapeptide and known tetrapeptide Lys-Glu-Asp-Ala.

The experiments were performed on 46 outbred white rats-males weighing 20010 g, obtained from the kennel "Kryukovo-Central" and kept in vivarium conditions at a temperature of 20-22oWith a light regime of 12/12 (light from 7 to 19 hours), food and water ad libitum. The acclimatization period prior to the beginning of the research, was not less than two weeks.

On locomotor activity in Auto-Track System (Columbus Instruments, USA) - test duration of five minutes and weight of the animals were divided into homogeneous groups. The anxiety level was determined using the Elevated Plus-Maze test the elevated plus maze" - PCL), raised to a height of 50 cm and collected from two open (h cm) and two closed sleeves (HH cm) with an open roof and Central square (junction) with a side of 10 cm, Animals were placed individually in the center of the PCL muzzle to the open sleeve and explored within 5 minutes following parameters: (a) the number of occurrences in open/closed sleeve; b) time during which the animal was in the open/closed sleeves.

Each animal was used only once. Use the completed the equivalent rats were injected with saline in a volume of 0.2 ml. Injection was performed for 30 min before testing. Mathematical processing of data was performed using Descriptive Statistics, correlation, and correlation analyses. Data on the impact of the declared heptapeptide on behavioral activity are shown in table 2. At doses of 20 and 100 mg/kg declared heptapeptide not significantly changed the level of anxiety of animals in the PCL. In three of the behavioral assessment of the status of the ATS no significant differences neither in the horizontal movement distance or in a vertical - the number of racks, the activity of animals. Declared heptapeptide at doses of 20 and 100 mg/kg does not affect psychomotor activity of animals in the considered tests.

Comparative data on the impact of known tetrapeptide Lys-Glu-Asp-Ala on behavioral activity are shown in table 3. In three of the behavioral assessment of the status of the ATS system demonstrated a gradual decrease horizontal and vertical locomotor activity of animals when injected them into the system. Injection tetrapeptide reduced the effect of repeated testing. The tendency to preserve the original motor and exploratory activity was dose-dependent and most vyrewatch, causing a decrease in time spent in the open sleeve PCL almost 5-fold (p<0.05) and the number of outputs in the open sleeve 3 times. Thus, known tetrapeptide affects the behavior of animals and has adverse psychomotor activity. The proposed Hexapeptide has a selective effect and does not affect psychomotor activity.

Example 3. Activity proposed heptapeptide to influence the endogenous opioid system has been evaluated for its inhibitory action on enkephalinergic enzymes in blood plasma. Effects on endogenous opioid system is one of the possible mechanisms of action of heptapeptide.

The half-life of regulatory peptides in the body, as a rule, does not exceed a few minutes. In the tissues of the body has a set enkephalinergic enzymes, reduce twice the concentration of endogenous peptides for 1-2 minutes In the hydrolysis participate amino peptidases, determine approximately 70% of the total enkephalinergic activity, as well as a number diamino - and dicarboximides. The effect of peptide inhibitors enkephalinergic enzymes leads to increased time of exposure of endogenous opioid peptides on body tissues, causing effectively in vitro on the rate of the enzymatic degradation of [3H]LEU-enkefalina (120 CI/mm).

The incubation mixture (final volume 50 ál) contained 4 µci (660 nm) [3H]LEU-enkefalina, 50 μm of heptapeptide, 25 mm Tris-Hcl (pH 7.4) and 0.15 M NaCl. The reaction was started by adding to the incubation mixture of 5 μl of serum obtained by the standard method from healthy donors. Incubation was carried out at a temperature of 37oC for 30 minutes and terminated by adding 5 μl of 0.2 M Hcl. The products of hydrolysis of radioactive lei-enkefalina were separated by chromatography on HPLC columns. Data analysis of products of enzymatic hydrolysis of [3H] LEU-enkefalina in the presence of 50 μm of heptapeptide and without it are given in table 4.

Shows the inhibiting effect of heptapeptide activity enkephalinergic enzymes of human serum. The degree of transformation lei-enkefalina decreased about two times for incubation mixture containing 50 μm of heptapeptide. In the presence of heptapeptide the content of the minor products of the enzymatic hydrolysis associated with the action diamino - and dicarboximides, was less than 1%. Declared heptapeptide was a more effective inhibitor than leupeptin used as a nonspecific enkephalinase inhibitor and denials twice (IC50), is about 100 μm.

Thus, hepatocytes old rats found high gerontological effect of peptide Gatlif. The intensity of protein synthesis in hepatocytes old rats almost doubled while simultaneously increasing the amplitude of the rhythm of protein synthesis in half after 24 hours after introduction into the culture medium of the peptide at a concentration of 0.005 ág/ml (6 nmol).

Our findings may indicate that at doses of 20 and 100 mg/kg intraperitoneal injection, heptapeptide does not affect psychomotor activity of animals in the considered behavioral tests. This indicates a selective effect of heptapeptide and no psychotropic effects in the doses.

The study of the ability of heptapeptide influence on the biochemical parameters of the endogenous opioid system has shown that it has a pronounced inhibitory effect on serum enzymes degradation of enkephalins. Heptapeptide was more effective than the known peptidase inhibitor, as leupeptin.

Sources of information 1. Brodsky C. J., Khavinson C. H., Zolotarev Y. A., Nechaev N. In., Malinin centuries , Novikova I.e., Gvazava, I., Fateyeva Century. And. Influence PE-521.

2. Pickart L., Thaler M. M. Tripeptide in human serum which prologs survival of normal liver cells and stimulates growth in neoplastic liver. Nature new biology, 1973, V. 243, S. 85-87.

3. Khavinson C. H. Patent of the Russian Federation 2166957 AND 61 TO 38/07, B 14, 2001.

4. Brodsky C. I., Nechaev N. In., Terek Century. Century. and other serum-free medium, preserving normal morphology and a high level of protein synthesis in hepatocytes in vitro. Izvestiya (Ser. Biol). 1996. 4. 398-401.


Heptapeptide lysyl-glutamyl-aspartyl-alanyl-prolyl-glycyl-Proline General formula Lys-Glu-Asp-Ala-Pro-Gly-Pro with stimulating and regulating effect on protein synthesis in hepatocytes.


Same patents:
The invention relates to medicine, in particular to ophthalmology, and can be used for the treatment of patients with diabetic retinopathy

The invention relates to the field of medical biotechnology

The invention relates to a method of producing tridecapeptide formula I: H-His-Gly-Val-Ser-Gly-His-Gly-Gln-His-Gly-Val-His-Gly-OH and aims to simplify the process and increase the yield of the target product, as well as Pentapeptide formula II: X-His(X)-Gly-Val-Ser(Y)-Gly-OH, which is an intermediate compound in the synthesis
The invention relates to medicine, namely to gynecology, and can be used for the treatment of benign diseases of the cervix: ectopia and erosion, eroded ectropion and other

The invention relates to oligopeptides comprising the amino acid sequence of the B-X-X-X-B-X-X-X-J-Tyr, which is Lys or Arg; X represents any amino acid, other than charged aliphatic amino acid or its D-isomer; and J is Gly, Lys or Arg; these amino acids are found in nature L-isomer, D-isomer and norleucine, and where specified Oligopeptide includes other than (a) naturally occurring sequencedomain antigen In human leukocyte (HLA-B) 75-84, (b) a naturally occurring sequence of the transmembrane sequence-chain T-cell receptor of human rights and (in) consistency, which is the mutant with respect to either (a) or (b) having no more than two mutations as an active part of the above oligopeptides; the method of suppressing the activation limfozitah cells, the method of transplantation of donor organs or mammalian cells, methods of inhibiting protein synthesis of inflammatory cytokines by cells capable of producing the specified protein inflammatory cytokine, the method of suppressing an inflammatory response in a mammal, the method of modulation of the activity hemade the
The invention relates to a group of new protected linear peptides containing the amino acid sequence, which can be used as starting compounds to obtain RGD-containing cyclopeptides, the General formula


where R1is benzyl or tert-butyl; R2not equal to R1and is selected from the group of tert-butyl; benzyl; 4-methoxybenzyl; 4-nitrobenzyl; diphenylmethyl; 2,2,2-trichloroethyl; 2,2,2-trichloro-1,1-dimethylethyl; allyl; 9-fluorenylmethyl; carboxamidine; substituted 2-sulfonylated type AND-SO2-CH2-CH2- where a is substituted or unsubstituted phenyl or benzyl; R3is a hydrogen atom or a urethane protective group of the B1O-CO-, where1not equal to R1and can take values tert-butyl, benzyl, 4-methoxybenzyl, 9-fluorenylmethyl, 2-(4-nitrophenyloctyl)ethyl; or is a peptidyl containing from one to three amino acid residues; and the peptides, where R3- peptidyl structure E-Z-Y-X-, in which E is a hydrogen atom or a urethane protective group IN2O-CO-, where2not equal to R1and can take values tert-butyl; benzyl; 4-methoxybenzyl; 9-fluorenylmethyl; 2-(4-nitrophen is IN3O-CO-, in which3= R1attached to the omega-amino group; Z can take values Phe or D-Phe

The invention relates to a new compound - peptide of General formula Thr-Gly-Glu-Asn-His-Arg, possessing the biological activity of inducing differentiation and inhibiting cell proliferation in tumors and activity of the tread and the normalizing action on the vital processes of mammalian cells obtained by the method of solid-phase peptide synthesis by sequential growth of the peptide chain and having the following properties: mol

FIELD: medicine, cardiology.

SUBSTANCE: the suggested method should be performed at the background of medicinal therapy with preparations out of statins group, tevetene, polyoxidonium and conducting seances of plasmapheresis by removing 800 ml plasma twice weekly with N 5 due to additional intramuscular injection of immunophan 0.005%-1.0 with N 10 and fluimucyl 300 mg intravenously daily with N 5-10, total course of therapy lasts for 2 mo. The method provides modulation of leukocytic functional activity, moreover, due to altered cytokine profile and, thus, through disintegration of protein-lipid complexes participating in the development of atherosclerotic platelets.

EFFECT: higher efficiency of therapy.

3 ex

FIELD: medicine, phthisiology, anesthesiology.

SUBSTANCE: during the day of operation one should perform autohemotransfusion, then introduce epocrine intravenously by drops at the dosage of 50-200 U/kg patient's body weight; next day after interference one should inject epocrine subcutaneously at the dosage of 25-100 U/kg; at hematocrit level being below 35% 48 h after operation it is necessary to repeat subcutaneous injection of the above-mentioned preparation at the dosage not exceeding 50 U/kg. The present innovation favors hemopoiesis stimulation in postoperational period, that, in its turn, accelerates postoperational rehabilitation in patients of this group and enables, also, to avoid allotransfusions being dangerous because of immunoconflicting reactions.

EFFECT: higher efficiency of compensation.

1 ex, 1 tbl

FIELD: pharmaceutical chemistry, medicine.

SUBSTANCE: in the suggested composition one should apply heptapeptide of Met-Glu-His-Phe-Pro-Gly-Pro sequence (heptapeptide A) for treating ischemic insult due to introducing 2 drops of compositions into each nasal canal 5-6 times daily for 10 d at disease of average severity degree, and in case of severe degree - per 3 drops of the present composition into each nasal canal 7 times daily for 10 d. The present innovation provides increased efficiency at decreased concentration of heptapeptide without any side effects.

EFFECT: higher efficiency of therapy.

2 cl, 6 dwg, 8 ex, 5 tbl

FIELD: genetic engineering, medicine.

SUBSTANCE: invention relates to T-cell receptor sequence being detected in patients with extended sclerosis and is useful in diagnosis and therapy. Oligonucleotide including sequence which represents or is derived from 5'-CTAGGGCGGGCGGGACTCACCTAC-3' or nucleotide sequence being fully complementary thereto. Oligonucleotide together with nuclear acid including nearly 15-30 oligonucleotides, which doesn't comprise oligonucleotide sequence and presents in region from Vβ to Jβ of Vβ13.1 gene in T-cell Vβ13.1-subgroup, wherein oligonucleotide and nuclear acid sequences don't present in the same chain of pair sequences of Vβ13.1 gene, is used in Vβ13.1 gene part amplification. In method for detection of LGRAGLTY motive, which is present in T-cell receptors of T-cell Vβ13.1-subgroup, oligonucleotide is used in combination with labeling particle. Once LGRAGLTY motive is detected, development monitoring and treatment are carried out by removing of LGRAGLTY motive-containing peptide.

EFFECT: simplified methods for detection of LGRAGLTY motive in T-cell receptors and treatment of patients with extended sclerosis.

21 cl, 7 dwg, 3 tbl, 3 ex

FIELD: medicine.

SUBSTANCE: peptide of the following formula: X-Pro-Gly-P, where X = Thr-Lys-Pro-Arg-; Lys-pro-Arg-; pro-Arg-; Arg-, being of untiulcerous activity. They should be applied at intraperitoneal injection at the dosage of 0.58-3.20 mcM g/kg for preventing and treating ulcers of gastro-intestinal tract.

EFFECT: higher efficiency and prophylaxis.

4 dwg, 5 ex

FIELD: chemistry of peptides, medicine, oncology, pharmaceutical chemistry.

SUBSTANCE: invention relates to the development of medicinal agent of peptide nature eliciting an antitumor effect and can be used in treatment of endocrine and hormone-dependent tumors. Agent represents peptide of the general formula: . Invention provides enhancement of the therapeutic effect and reducing toxicity.

EFFECT: valuable medicinal properties of agent.

3 cl, 4 tbl, 2 ex

FIELD: medicine, surgery.

SUBSTANCE: one should introduce solution "Rheamberin 1.5%"intravenously with infusomates at the dosage of 5 ml/kg/d during the next 5 d. Then, 1-2 h later, one should infuse intravenously "Dalargin" at 30 mg/kg/d dissolved in 60 ml 0.9% sodium chloride at the rate of 120 ml/h for 5 d. Additionally, 4-5 h after "Dalargin" injection it is necessary to perform daily intravenous He-Ne laser irradiation of blood beginning since the first day at wave length being 0.63 mcm, power 1 mW, exposure 50-60 min, course lasts for 5 d. The method enables to interrupt intestinal paresis in case of vertebral traumas and wounds in earlier terms.

EFFECT: higher efficiency of therapy.

1 ex

FIELD: medicine, first aid, anesthesiology, resuscitation, surgery.

SUBSTANCE: along with conventional medicinal preparations applied to treat shock one should introduce crystalloids into central vein in certain sequence: 7.5% and 0.9%-sodium chloride solution, 5%-glucose solution, and, also, infucol and similar-group plasma; after stabilizing arterial pressure one should introduce, additionally, either mildronate, or dalargin at certain dosages. The present innovation enables to restore the volume of extracellular liquid in the shortest period of time at decreased volume of infusion that, in its turn, favors to remove shock and prevent other possible further complications.

EFFECT: higher efficiency.

3 ex

FIELD: bioorganic chemistry.

SUBSTANCE: invention provides somatostatin agonists of general formula: A1-cyclo{Cys-A2-D-Trp-A3-A4-Cys}-A5-Y1 (I), wherein A1 represents aromatic D- or L-α-amino acid selected from Phe, D-Phe, Tyr, D-Tyr, β-Nal, D-β-Nal, Cha, or D-Cha; A2 aromatic α-amino acid selected from Phe, Tyr, β-Nal, and Cha; A3 Lys or Orn; A4 β-hydroxyvaline, Ser, hSer, or Thr; A5 β-hydroxyvaline, Ser, hSer, or Thr; and Y1 represents NH2; amide nitrogen atoms of peptide groups and amine group of A1 in compound I are optionally substituted by methyl group, provided that at least one methyl group is available and that compound I cannot have following formula: D-Phe-cyclo{Cys-Phe-D-Trp-Lys-(N-Me-Thr)-Cys}-Thr-NH-2. pharmaceutically acceptable salts of compound I are also claimed.

EFFECT: expanded synthetic possibilities in peptide synthesis.

24 cl, 2 tbl, 18 ex

Oligopeptides // 2260597

FIELD: organic chemistry, peptides, biochemistry.

SUBSTANCE: invention describes oligopeptide or its salt taken among the group consisting of oligopeptide (1) and (2): Lys-Ser-Ile-Glu-Gln-Ser-Cys-Asp-Gln-Asp-Glu (I), Ser-Ile-Glu-Gln-Ser-Cys-Asp-Gln-Asp-Glu (II); Ser-Ile-Glu-Gln-Ser-Cys-Asp-Gln-Asp (III); Ser-Ile-Glu-Gln-Ser-Cys-Asp-Gln (IV); Ser-Ile-Glu-Gln-Ser-Cys-Asp (V); Ser-Ile-Glu-Gln-Ser-Cys (VI); Ile-Glu-Gln-Ser-Cys-Asp-Gln-Asp-Glu (VII); Glu-Gln-Ser-Cys-Asp-Gln-Asp-Glu (VIII); Gln-Ser-Cys-Asp-Gln-Asp-Glu (IX); 2) oligopeptide with amino acid sequence obtained by deleting by C- or N-end of one or some amino acids in any amino acid sequence (I)-(IX), and the modified oligopeptide representing oligopeptide biotinylated or dimerized by sulfhydryl group of cysteine residue based on oligopeptide determined in (1) or (2). Oligopeptides elicit activity with respect to hair growth stimulation.

EFFECT: valuable properties of oligopeptides.

11 cl, 6 dwg, 4 ex